Chicago—When added to the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), the experimental anti-CD20 monoclonal antibody ublituximab produces a large improvement in antitumor activity, according to Phase III results in patients who had in most cases received another anti-CD20 agent in prior lines of therapy.
The primary end point of this study was the objective response rate (ORR), which climbed from 45% in